药品批发

Search documents
★市场准入再放宽 2025年版负面清单继续做减法
Zheng Quan Shi Bao· 2025-07-03 01:56
Core Viewpoint - The 2025 version of the Market Access Negative List has been released, reducing the number of restrictions from 117 to 106, indicating a continued effort to simplify market access and promote economic development [1][2]. Group 1: Changes in the Negative List - The new list directly removes 8 national measures, including changing the seal engraving industry from a licensing system to a filing system [2]. - A total of 17 local measures have been deleted, affecting sectors such as transportation logistics and vehicle rental services [2]. - Eight national measures have been relaxed, including the establishment of television production units and the management of drug wholesale and retail enterprises [2]. Group 2: New Regulations and Emphasis - The new list further regulates access to new industries, including unmanned aerial vehicles and e-cigarettes, while emphasizing the importance of safety in key areas such as finance and production [3]. - It specifies that non-financial institutions must not use terms like "futures company" in their registration names or business scopes, reinforcing regulations against unauthorized futures activities [3]. Group 3: Market Access Barrier Removal - The government will initiate actions to clear market access barriers, aiming to eliminate unreasonable regulations and practices that hinder market entry [3]. - A long-term mechanism will be established for collecting, verifying, and reporting cases of market access barriers to ensure a fair market environment [3].
华润医药收购震元医药51%股权案近日公示,并购将加速后者业务转型
IPO早知道· 2025-01-09 15:17
华润医药将有单独控制权。 本文为IPO早知道原创 作者|罗宾 微信公众号|ipozaozhidao 据IPO早知道消息,1月8日,国家市场监管总局公示了"华润医药商业集团有限公司收购绍兴震元医 药经营有限责任公司股权案"。 本文由公众号IPO早知道(ID:ipozaozhidao)原创撰写,如需转载请联系C叔↓↓↓ 华润医药商业集团有限公司(下称"华润医商")与浙江震元股份有限公司(下称"浙江震元", 000705.SZ)、绍兴震元医药经营有限责任公司(下称"震元医药")签署协议,华润医商通过进场 摘牌以现金增资的方式收购震元医药51%的股权。 震元医药主要从事药品批发业务。交易前,浙江震元持有目标公司100%的股权,单独控制震元医 药。交易后,华润医商将持有震元医药51%的股权,浙江震元将持有后者49%的股权,且华润医商 单独控制震元医药。 此前,浙江震元于12月24日对上述拟议交易进行了披露,震元医药拟引入华润医药商业为战略投资 者,增资价格为1.439517元/元注册资本,增资金额为1.1986亿元。浙江震元在此次增资扩股中放 弃优先认购权。震元医药将不再纳入公司合并财务报表范围。 此次并购重组旨在优化 ...